Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 15 mg, 30 mg, 45 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Summary
- Dacomitinib (Vizimpro) is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.
- A total of 11 systematic reviews and meta-analyses were reviewed, providing insights into dacomitinib's safety and effectiveness in treating NSCLC.
- Compared to other EGFR-TKIs, dacomitinib demonstrated superior progression-free survival (PFS), overall survival (OS), and a greater tumor burden response across several studies.
- In Asian populations, including Japanese patients diagnosed with EGFR+ NSCLC, dacomitinib was found to be highly effective at prolonging survival while eliciting a lower risk of adverse events compared to other treatments.
- For NSCLC patients with brain metastases, regardless of uncommon mutation presence, dacomitinib has potential intracranial tumor control capabilities suggesting its broader applicability in such cases.
- Regarding hepatotoxicity profile comparison among different drugs used for similar indications as Vizimpro; it was associated with a lower risk for alanine transaminase elevation than gefinitinb indicating potentially less liver toxicity issues related to this drug use.
- However, general adverse events like diarrhea and rash were more commonly associated with the use of Dacamotinab when compared against afatinib or erlotinb which are also used as first line therapy options in certain types on Non-Small Cell Lung Cancer.
- Due consideration should be given by health professionals prescribing this medication due its higher rate of side effects despite showing promising results especially amongst Asian population groups suffering from Non Small Cell Lung Carcinoma.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vizimpro (dacomitinib) Prescribing Information. | 2020 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. | 2022 | Journal of the National Comprehensive Cancer Network |
| Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. | 2021 | Journal of Clinical Oncology |
| Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2020 | EMSO |
| The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. | 2019 | International Journal of Clinical Oncology |
| SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). | 2018 | Clinical and Translational Oncology |